Consistently, the HOXB5 gene expression levels in AML patients with NPM1, FLT3, or DNMT3A mutations were higher than those in AML patients without gene mutations (Figure 2B and Supplementary Figure 4B). This evidence concerns the gene FLT3 and acute myeloid leukemia.